Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bertek And Amide Sue FDA To Remove Unapproved Digoxins

Executive Summary

Jerome Stevens/Duramed's digoxin tablets should be removed from the market, Bertek and Amide maintain in an Oct. 4 complaint against FDA for declaratory and injunctive relief in Washington, D.C. district court.

You may also be interested in...



King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement

King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004

King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement

King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004

Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years

Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel